GSK's Cervarix is First HPV Vaccine Approved for China Use

GSK announced China approval for Cervarix™, a human papillomavirus (Types 16, 18) vaccine, as a preventative for cervical cancer, the first HPV vaccine approved for use in China. GSK said it is willing to work with China authorities towards a "innovative pricing" strategy so that the vaccine is included in public cancer immunization programs. The vaccine is indicated for use in girls and women aged 9-25 years with a three-dose regimen. GSK China expects to launch Cervarix in early 2017. More details.... Stock Symbol: (NYSE: GSK) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.